Results 121 to 130 of about 101,700 (245)

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

BCR–ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ

MedComm, Volume 7, Issue 5, May 2026.
There is global immunosuppression during CML initiation and progression, which is directly driven by BCR–ABL1 expressing CML cells. On one hand, the BCR–ABL1 oncogene drives the differentiation of leukemia cells toward the neutrophil lineage. On the other hand, the oncogene also transcriptionally activates master immune regulators, including arginase ...
Xiaocui Lu, Hui Fang, Yuan Liu, Chang Liu, Xuexiu Fang, Atsuko Matsunaga, Stephanie F. Mori, Ting Zhang, Gavin Wang, George I. Zhou, Miao Yu, Haocheng Ding, Jorge Cortes, Bo Cheng, Tianxiang Hu   +14 more
wiley   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Targeting CDK6 and BCL2 Exploits the MYB Addiction of Ph+ Acute Lymphoblastic Leukemia [PDF]

, 2018
Philadelphia chromosome–positive acute lymphoblastic leukemia (Phþ ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1–dependent and –
Addya, Sankar, Calabretta, Bruno, De Dominici, Marco, Ferrari, Anna, Fortina, Paolo, Iacobucci, Ilaria, Mariani, Samanta A., Martinelli, Giovanni, Peterson, Luke F., Porazzi, Patrizia, Rambaldi, Alessandro, Soliera, Angela Rachele, Spinelli, Orietta   +12 more
core   +1 more source

Cancer Biomarker Test Utilization and Reimbursement in Australia: A National Analysis of Medicare Data

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Biomarker testing plays a critical role in precision oncology by guiding targeted therapy selection. In Australia, public reimbursement for somatic tumor biomarker tests has expanded over the past decade, yet national data on utilization patterns, equity of access, and public expenditure remain limited. We identified all cancer biomarker tests
Leping Kong, Christine Y. Lu
wiley   +1 more source

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose

Blood and Lymphatic Cancer: Targets and Therapy, 2015
Joanna Waclaw,1 Tomasz Sacha,1 Tomasz Stoklosa,21Department of Hematology, Jagiellonian University Collegium Medicum, Kraków, 2Department of Immunology, Medical University of Warsaw, Warsaw, Poland Abstract: Imatinib was the first tyrosine kinase
Waclaw J, Sacha T, Stoklosa T
doaj  

A Case of Recurrent Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Adenocarcinoma Following Imatinib Discontinuation

Pulmonary Circulation
Pulmonary tumor thrombotic microangiopathy (PTTM) is a severe and fatal disease that rapidly causes pulmonary hypertension (PH). While imatinib shows potential for treating PH related to PTTM, it remains unclear if imatinib should continue or be ...
Atsumasa Kurozumi, Shun Minatsuki, Masaru Hatano, Takayuki Tsujimoto, Gota Fujisawa, Satoshi Ishii, Hiroki Yagi, Mai Shimbo, Masako Ikemura, Mitsuhiro Fujishiro, Norihiko Takeda   +10 more
doaj   +1 more source

Discovery of [1,2,4]triazolo[1,5‐a]pyrimidine‐Imatinib Hybrids With Selective Cytotoxic Activity: A Mechanistically Divergent Series From Direct BCR‐ABL1 Inhibition

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Discovery of imatinib–triazolopyrimidine hybrids with selective cytotoxicity and a mechanism distinct from classical BCR‐ABL1 inhibition. This bioisosteric strategy introduces a novel compounds, paving the way for innovative antileukemic therapies with differentiated profiles.
Stefany Castro Bazan Moura, Andressa Paula de Oliveira, Joao de Mello Rezende Neto, Rafael Ferreira Dantas, Floriano Paes Silva‐Jr, Luiz Claudio Pimentel, Mayara Salles do Nascimento Carvalho, Debora Inacio Leite, Daiane Vitoria da Silva, Monica Macedo Bastos, Nubia Boechat   +10 more
wiley   +1 more source